Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Biovena Science LLC currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's current workload is spread across 2 different administrative segments of the patent office.
The busiest examiner for the company is AL-AWADI, DANAH J, who is responsible for 1 busiest examiner pending office action. This 1 action represents 1 of the 2 pending office actions identified in the portfolio. With 2 distinct examiners involved, the prosecution is not concentrated under 1 individual.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AL-AWADI, DANAH J | 1 | 54.2% | +13.4% |
| MITCHELL, EDWIN COLEMAN | 1 | 32.1% | +64.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17277342 | Octreotide Microsphere-Based Arterial Embolization for Treating Obesity | MITCHELL, EDWIN COLEMAN | 139d overdue |
| 17277400 | Flutamide Microsphere-Based Arterial Embolization for Treating Prostate Disorders | AL-AWADI, DANAH J | 39d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17277400 | Flutamide Microsphere-Based Arterial Embolization for Treating Prostate Disorders | AL-AWADI, DANAH J | 1615 | §103 | Final Rejection | 39d | Pending | Mar 18, 2021 |
| 17277342 | Octreotide Microsphere-Based Arterial Embolization for Treating Obesity | MITCHELL, EDWIN COLEMAN | 1619 | §103 | Final Rejection | 139d overdue | Pending | Mar 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial